In a small, randomized, open-label study, patients fared better with a combination of vancomycin and rifampin than with vancomycin monotherapy.
Among patients with staphylococcal bone or heart-valve infections, outcomes have been improved with antibiotic combinations that include rifampin. But what is the effect of adding rifampin to vancomycin for treating nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia?
To find out, researchers in Seoul, South Korea, conducted a randomized, open-label trial between July 2004 and December 2006 involving 93 critically ill nonneutropenic adults with gram-positive nosocomial pneumonia. Forty-six patients received intravenous vancomycin (1 g) plus oral rifampin (300 mg) twice daily; 47 received intravenous vancomycin only. Five patients in each group were later excluded because MRSA was not detected or their isolates proved resi…
Reviewing Author
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection